{
    "nctId": "NCT00337649",
    "briefTitle": "A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer",
    "officialTitle": "An Open-label Study to Evaluate the Effect of Combination Therapy With Epothilone D and Herceptin on Tumor Response in Patients With HER-2 Overexpressing Locally Advanced or Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 27,
    "primaryOutcomeMeasure": "Phase I: Number of Participants with a Dose-Limiting Toxicity",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* women \\>=18 years;\n* locally advanced or metastatic breast cancer;\n* HER-2 overexpression (FISH + or IHC 3+);\n* \\>=1 measurable lesion;\n* up to one prior anthracycline-based chemotherapy regimen in a metastatic setting.\n\nExclusion Criteria:\n\n* pre-existing neuropathy \\>=grade 2;\n* known CNS metastases;\n* congestive heart failure, or myocardial infarction within the last 6 months;\n* previous malignancies in last 5 years, except for cured basal cell cancer of the skin, or cancer in situ of the cervix.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}